Postacute sequelae of COVID-19 at 2 years
Benjamin Bowe, Yan Xie, Ziyad Al-Aly, Benjamin Bowe, Yan Xie, Ziyad Al-Aly
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to postacute sequelae in multiple organ systems, but evidence is mostly limited to the first year postinfection. We built a cohort of 138,818 individuals with SARS-CoV-2 infection and 5,985,227 noninfected control group from the US Department of Veterans Affairs and followed them for 2 years to estimate the risks of death and 80 prespecified postacute sequelae of COVID-19 (PASC) according to care setting during the acute phase of infection. The increased risk of death was not significant beyond 6 months after infection among nonhospitalized but remained significantly elevated through the 2 years in hospitalized individuals. Within the 80 prespecified sequelae, 69% and 35% of them became not significant at 2 years after infection among nonhospitalized and hospitalized individuals, respectively. Cumulatively at 2 years, PASC contributed 80.4 (95% confidence interval (CI): 71.6-89.6) and 642.8 (95% CI: 596.9-689.3) disability-adjusted life years (DALYs) per 1,000 persons among nonhospitalized and hospitalized individuals; 25.3% (18.9-31.0%) and 21.3% (18.2-24.5%) of the cumulative 2-year DALYs in nonhospitalized and hospitalized were from the second year. In sum, while risks of many sequelae declined 2 years after infection, the substantial cumulative burden of health loss due to PASC calls for attention to the care needs of people with long-term health effects due to SARS-CoV-2 infection.
Conflict of interest statement
B.B. reports receiving consultation fees from AstraZeneca. Z.A.A. reports receiving consultation fees from Gilead Sciences and funding (unrelated to this work) from Tonix Pharmaceuticals. Z.A.A. and Y.X. report consulting (uncompensated) for Pfizer.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Figures
References
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:408. doi: 10.1038/s41579-023-00896-0.
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–264. doi: 10.1038/s41586-021-03553-9.
- Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583–590. doi: 10.1038/s41591-022-01689-3.
- Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19. BMJ. 2022;376:e068993. doi: 10.1136/bmj-2021-068993.
- Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311–321. doi: 10.1016/S2213-8587(22)00044-4.
- Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461–1467. doi: 10.1038/s41591-022-01840-0.
- Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 2022;28:2406–2415. doi: 10.1038/s41591-022-02001-z.
- Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J. Am. Soc. Nephrol. 2021;32:2851–2862. doi: 10.1681/ASN.2021060734.
- Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 2021;12:6571. doi: 10.1038/s41467-021-26513-3.
- Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 2022;28:2398–2405. doi: 10.1038/s41591-022-02051-3.
- Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023;11:120–128. doi: 10.1016/S2213-8587(22)00355-2.
- Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 2023;14:983. doi: 10.1038/s41467-023-36223-7.
- Taquet M, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9:815–827. doi: 10.1016/S2215-0366(22)00260-7.
- Huang L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir. Med. 2022;10:863–876. doi: 10.1016/S2213-2600(22)00126-6.
- Yang X, et al. Two-year health outcomes in hospitalized COVID-19 survivors in China. JAMA Netw. Open. 2022;5:e2231790. doi: 10.1001/jamanetworkopen.2022.31790.
- Fjelltveit EB, et al. Symptom burden and immune dynamics 6 to 18 months following mild severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2): a case–control study. Clin. Infect. Dis. 2023;76:e60–e70. doi: 10.1093/cid/ciac655.
- Li D, et al. Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study. Emerg. Microbes Infect. 2022;11:2680–2688. doi: 10.1080/22221751.2022.2133639.
- Krumholz HM. Post-hospital syndrome—an acquired, transient condition of generalized risk. N. Engl. J. Med. 2013;368:100–102. doi: 10.1056/NEJMp1212324.
- Emanuel EJ, Osterholm M, Gounder CR. A national strategy for the ‘new normal’ of life with COVID. JAMA. 2022;327:211–212. doi: 10.1001/jama.2021.24282.
- Al-Aly Z, Agarwal A, Alwan N, Luyckx VA. Long COVID: long-term health outcomes and implications for policy and research. Nat. Rev. Nephrol. 2023;19:1–2. doi: 10.1038/s41581-022-00652-2.
- Al-Aly Z. Diabetes after SARS-CoV-2 infection. Lancet Diabetes Endocrinol. 2023;11:11–13. doi: 10.1016/S2213-8587(22)00324-2.
- Al-Aly Z. Prevention of long COVID: progress and challenges. Lancet Infect. Dis. 2023;23:776–777. doi: 10.1016/S1473-3099(23)00287-6.
- Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–1615. doi: 10.1001/jama.2022.18931.
- Arnold, N., Sohn, M., Maynard, C., & Hynes, D. M. VIReC Technical Report 2. VA-NDI Mortality Data Merge Project. (VA Information Resource Center, 2006).
- Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible – the Neighborhood Atlas. N. Engl. J. Med. 2018;378:2456–2458. doi: 10.1056/NEJMp1802313.
- Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 2022;28:2398–2405. doi: 10.1038/s41591-022-02051-3.
- Xie Y, Bowe B, Maddukuri G, Al-Aly Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with COVID-19 and seasonal influenza: cohort study. BMJ. 2020;371:m4677. doi: 10.1136/bmj.m4677.
- Cohen K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414. doi: 10.1136/bmj-2021-068414.
- Daugherty SE, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.
- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–427. doi: 10.1016/S2215-0366(21)00084-5.
- Bowe B. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin. J. Am. Soc. Nephrol. 2020;16:14–25. doi: 10.2215/CJN.09610620.
- Cai M, Bowe B, Xie Y, Al-Aly Z. Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open. 2021;11:e047369. doi: 10.1136/bmjopen-2020-047369.
- Xie Y, Choi T, Al-Aly Z. Risk of death in patients hospitalized for COVID-19 vs seasonal influenza in fall-winter 2022-2023. JAMA. 2023;329:1697–1699. doi: 10.1001/jama.2023.5348.
- Taquet M, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.
- Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. JAMA Intern. Med. 2023;183:554–564. doi: 10.1001/jamainternmed.2023.0743.
- Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;380:e072705. doi: 10.1136/bmj-2022-072705.
- Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;381:e073312. doi: 10.1136/bmj-2022-073312.
- Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. doi: 10.1136/bmj-2022-074572.
- Inker LA, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 2021;385:1737–1749. doi: 10.1056/NEJMoa2102953.
- Harrell, F. E. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis (Springer Cham, 2015).
- Schneeweiss S, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512–522. doi: 10.1097/EDE.0b013e3181a663cc.
- Wei Y, et al. Short term exposure to fine particulate matter and hospital admission risks and costs in the Medicare population: time stratified, case crossover study. BMJ. 2019;367:l6258. doi: 10.1136/bmj.l6258.
- Aubert CE, et al. Best definitions of multimorbidity to identify patients with high health care resource utilization. Mayo Clin. Proc. Innov. Qual. Outcomes. 2020;4:40–49. doi: 10.1016/j.mayocpiqo.2019.09.002.
- Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP). (2022).
- Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 2010;87:48–51. doi: 10.1038/clpt.2009.198.
- Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug–drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J. Am. Geriatr. Soc. 2014;62:447–453. doi: 10.1111/jgs.12695.
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 2011;46:399–424. doi: 10.1080/00273171.2011.568786.
- Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat. Med. 2009;28:3083–3107. doi: 10.1002/sim.3697.
- Kyu HH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859–1922. doi: 10.1016/S0140-6736(18)32335-3.
- Hanson SW, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–1615. doi: 10.1001/jama.2022.18931.
- Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- IHME. GBD results. (2021).
- Fireman B, et al. Consequences of depletion of susceptibles for hazard ratio estimators based on propensity scores. Epidemiology. 2020;31:806. doi: 10.1097/EDE.0000000000001246.
- Ayoubkhani D, et al. Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.
- Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383–388. doi: 10.1097/EDE.0b013e3181d61eeb.
Source: PubMed